Group A Streptococcus vaccine

IVI, in collaboration with EuBiologics, ASAVI, and GVGH, is developing a Group A Streptococcus (GAS) vaccine to address a critical unmet global health need. Despite GAS infections causing significant morbidity and mortality, particularly due to Rheumatic Heart Disease, no vaccine currently exists. The vaccine aims to target multiple pathogenesis mechanisms. This project supports technology transfer from GVGH to EuBiologics, leveraging EuBiologics’ GMP manufacturing expertise and WHO prequalification track record. Activities include manufacturing drug substance and drug product for Phase IIa trials, stability testing, and adjuvant down-selection. The vaccine targets infants and young children in low- and middle-income countries and could potentially reduce antibiotic prescriptions by up to 87%, supporting efforts to combat antimicrobial resistance.